Literature DB >> 19604262

Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

S G R Smalley1, P A Barrow, N Foster.   

Abstract

Since the late 1970s a number of laboratories have studied the role of vasoactive intestinal peptide (VIP) in inflammation and immunity. These studies have highlighted the dramatic effect of VIP on immune cell activation and function, and studies using animal models of disease have indicated that VIP has significant therapeutic and prophylactic potential. This review will focus on the effects of VIP on innate immune cell function and discuss the therapeutic potential for VIP in inflammatory diseases of humans.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19604262      PMCID： PMC2730848          DOI： 10.1111/j.1365-2249.2009.03956.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN： 0009-9104            Impact factor:   4.330


  95 in total

1.  Vasoactive intestinal peptide (VIP) receptor type 2 (VPAC2) is the predominant receptor expressed in human thymocytes.

Authors:  M L Lara-Marquez; M S O'Dorisio; B Karacay
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18.

Authors:  S H Kim; M Eisenstein; L Reznikov; G Fantuzzi; D Novick; M Rubinstein; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

Review 3.  Inflammatory signals in dendritic cell activation and the induction of adaptive immunity.

Authors:  Olivier Joffre; Martijn A Nolte; Roman Spörri; Caetano Reis e Sousa
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

4.  Stabilization of vasoactive intestinal peptide by lipids.

Authors:  G Gololobov; Y Noda; S Sherman; I Rubinstein; J Baranowska-Kortylewicz; S Paul
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

5.  NF-kappa B and STAT5 play important roles in the regulation of mouse Toll-like receptor 2 gene expression.

Authors:  T Musikacharoen; T Matsuguchi; T Kikuchi; Y Yoshikai
Journal:  J Immunol       Date:  2001-04-01       Impact factor: 5.422

Review 6.  Vasoactive intestinal peptide as a healing mediator in Crohn's disease.

Authors:  A Arranz; C Abad; Y Juarranz; J Leceta; C Martinez; R P Gomariz
Journal:  Neuroimmunomodulation       Date:  2008-07-29       Impact factor: 2.492

7.  Receptor-independent mechanisms are involved in the priming of neutrophil's oxidase by vasoactive intestinal peptide.

Authors:  C Pedrera; M Lucas; L Bellido; M A López-González
Journal:  Regul Pept       Date:  1994-12-15

8.  Vasoactive intestinal peptide suppresses toll-like receptor 4 expression in macrophages via Akt1 reducing their responsiveness to lipopolysaccharide.

Authors:  Alicia Arranz; Ariadne Androulidaki; Vassiliki Zacharioudaki; Carmen Martinez; Andrew N Margioris; Rosa P Gomariz; Christos Tsatsanis
Journal:  Mol Immunol       Date:  2008-03-11       Impact factor: 4.407

9.  Functional expression and tissue distribution of a novel receptor for vasoactive intestinal polypeptide.

Authors:  T Ishihara; R Shigemoto; K Mori; K Takahashi; S Nagata
Journal:  Neuron       Date:  1992-04       Impact factor: 17.173

10.  VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4(+) T cells.

Authors:  Mario Delgado; Allan Reduta; Vikas Sharma; Doina Ganea
Journal:  J Leukoc Biol       Date:  2004-03-12       Impact factor: 4.962
View more
  21 in total

1.  Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Linda D Hazlett
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

Review 2.  Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions.

Authors:  Mario Delgado; Doina Ganea
Journal:  Amino Acids       Date:  2011-12-03       Impact factor: 3.520

3.  Vasoactive intestinal peptide promotes gut barrier function against severe acute pancreatitis.

Authors:  Lu Zhongkai; Ye Jianxin; Chen Weichang
Journal:  Mol Biol Rep       Date:  2011-07-03       Impact factor: 2.316

4.  Vasoactive intestinal peptide signaling axis in human leukemia.

Authors:  Glenn Paul Dorsam; Keith Benton; Jarrett Failing; Sandeep Batra
Journal:  World J Biol Chem       Date:  2011-06-26

5.  Neuropeptide Levels as well as Neprilysin Activity Decrease in Renal Cell Carcinoma.

Authors:  Nuray Erin; Tümay İpekçi; Bahar Akkaya; İrem Hicran Özbudak; Mehmet Baykara
Journal:  Cancer Microenviron       Date:  2016-10-19

6.  The absence of the VPAC(2) receptor does not protect mice from Aspergillus induced allergic asthma.

Authors:  A E Samarasinghe; S A Hoselton; J M Schuh
Journal:  Peptides       Date:  2010-03-11       Impact factor: 3.750

Review 7.  VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies.

Authors:  Terry W Moody; Tetsuhide Ito; Nuramy Osefo; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-02       Impact factor: 3.243

8.  Vasoactive intestinal peptide maintains the nonpathogenic profile of human th17-polarized cells.

Authors:  Rebeca Jimeno; Javier Leceta; Carmen Martínez; Irene Gutiérrez-Cañas; Mar Carrión; Selene Pérez-García; Marina Garín; Mario Mellado; Rosa P Gomariz; Yasmina Juarranz
Journal:  J Mol Neurosci       Date:  2014-05-08       Impact factor: 3.444

9.  Identification of STOML2 as a putative novel asthma risk gene associated with IL6R.

Authors:  J A Revez; M C Matheson; J Hui; S Baltic; A James; J W Upham; S Dharmage; P J Thompson; N G Martin; J L Hopper; M A R Ferreira
Journal:  Allergy       Date:  2016-03-24       Impact factor: 13.146

10.  Colonic delivery of vasoactive intestinal peptide nanomedicine alleviates colitis and shows promise as an oral capsule.

Authors:  Shubha Priyamvada; Anoop Kumar; Seema Saksena; Hayat Onyuksel
Journal:  Nanomedicine (Lond)       Date:  2020-09-25       Impact factor: 5.307
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.